Insider Transactions in Q2 2021 at Werewolf Therapeutics, Inc. (HOWL)
Insider Transaction List (Q2 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 16
2021
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
9,285
+0.22%
|
$120,705
$13.37 P/Share
|
|
Jun 15
2021
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
7,958
+0.19%
|
$95,496
$12.95 P/Share
|
|
Jun 14
2021
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
306,055
+6.68%
|
$3,672,660
$12.75 P/Share
|
|
May 04
2021
|
Mpm Bio Ventures 2014, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
125,759
+3.8%
|
$2,012,144
$16.0 P/Share
|
|
May 04
2021
|
Mpm Bio Ventures 2014, L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
3,062,239
+34.98%
|
-
|
|
May 04
2021
|
Ansbert Gadicke > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
245,000
+3.54%
|
$3,920,000
$16.0 P/Share
|
|
May 04
2021
|
Ansbert Gadicke > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
5,965,775
+33.17%
|
-
|
|
May 04
2021
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
1,715,000
+25.3%
|
$27,440,000
$16.0 P/Share
|
|
May 04
2021
|
Ra Capital Management, L.P. |
BUY
Conversion of derivative security
|
Indirect |
2,253,583
+50.0%
|
-
|
|
May 04
2021
|
Luke Evnin |
BUY
Open market or private purchase
|
Indirect |
150,799
+3.4%
|
$2,412,784
$16.0 P/Share
|
|
May 04
2021
|
Luke Evnin |
BUY
Conversion of derivative security
|
Indirect |
3,671,965
+32.14%
|
-
|
|
May 04
2021
|
Hbm Healthcare Investments (Cayman) Ltd. > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
625,995
+50.0%
|
-
|
|
May 04
2021
|
Upmc > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
1,097,756
+34.98%
|
-
|
|
May 04
2021
|
Longwood Fund Iii Gp, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
250,000
+12.97%
|
$4,000,000
$16.0 P/Share
|
|
May 04
2021
|
Longwood Fund Iii Gp, LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
1,427,082
+34.98%
|
-
|
|
May 04
2021
|
Arkin Bio Ventures 2 L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
400,000
+16.35%
|
$6,400,000
$16.0 P/Share
|
|
May 04
2021
|
Arkin Bio Ventures 2 L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
1,646,634
+34.98%
|
-
|
|
May 04
2021
|
Taiho Ventures LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
312,500
+13.12%
|
$5,000,000
$16.0 P/Share
|
|
May 04
2021
|
Taiho Ventures LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
1,756,409
+34.98%
|
-
|
|
May 04
2021
|
Sphera Global Healthcare Management LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
475,000
+37.61%
|
$7,600,000
$16.0 P/Share
|
|
May 04
2021
|
Sphera Global Healthcare Management LP > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
312,997
+50.0%
|
-
|
|
May 04
2021
|
James E Flynn > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
800,000
+23.86%
|
$12,800,000
$16.0 P/Share
|
|
May 04
2021
|
James E Flynn > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
1,752,787
+50.0%
|
-
|
|
May 04
2021
|
Alon Lazarus |
BUY
Open market or private purchase
|
Indirect |
400,000
+16.35%
|
$6,400,000
$16.0 P/Share
|
|
May 04
2021
|
Alon Lazarus |
BUY
Conversion of derivative security
|
Indirect |
1,646,634
+34.98%
|
-
|
|
May 04
2021
|
Sakae Asanuma Director |
BUY
Open market or private purchase
|
Indirect |
312,500
+13.12%
|
$5,000,000
$16.0 P/Share
|
|
May 04
2021
|
Sakae Asanuma Director |
BUY
Conversion of derivative security
|
Indirect |
1,756,409
+34.98%
|
-
|